SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN - News) today reported its financial results for the third quarter and nine months ended September 30, 2007. The company reported a net loss of $39.0 million, or $0.57 per share, for the quarter ended September 30, 2007, which compares to a net loss of $31.2 million, or $0.47 per share, for the comparable 2006 quarter. The increase was driven largely by costs related to the preparation for approval and launch of rThrombin, which is currently undergoing FDA review. For the nine months ended September 30, 2007, the company’s net loss was $109.6 million, or $1.61 per share, compared to a net loss of $92.9 million, or $1.39 per share, for the comparable 2006 period.
